OXFORD, England, May 19, 2016 /PRNewswire/ --
Glide Technologies, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that it has initiated a clinical proof-of-concept study comparing its novel solid formulation of octreotide acetate with the currently marketed liquid product (Sandostatin®). Octreotide is approved for use in the treatment of acromegaly and certain neuroendocrine tumours, with the estimated market for immediate release liquid formulations exceeding $150 million.
The clinical study will compare the pharmacokinetic profile and bioavailability of the most widely used dose of Sandostatin (100 mcg) with Glide's octreotide solid dose formulation delivered via the company's novel needle-free solid dose injection system (SDI®). Glide's SDI® provides the potential for room temperature stable products and improved patient-friendly self-administration. The study is ongoing in the UK following approval from the Medicines and Healthcare products Regulatory Agency, and the results are expected in Q3 2016.
Dr Mark Carnegie-Brown, Glide Technologies' CEO, commented, "This clinical trial represents a significant milestone, providing Glide the opportunity to demonstrate both bioequivalence with the currently marketed Sandostatin® liquid product and the utility and patient acceptance of the SDI® delivery system. The clinical study builds on the highly encouraging pre-clinical data we have achieved with our octreotide, teriparatide and exenatide solid dose formulations, and we look forward to reporting the results in the coming months."
About Glide Technologies
Glide Technologies is a pharmaceutical development and device company focused on solid dose formulation of therapeutics and vaccines. These formulations provide room temperature stability, removing the need for product refrigeration and cold chain distribution. The company's products are based on its proprietary solid dose injector, the Glide SDI®, which offers the potential of improved compliance in long-term therapy and enhanced immune responses to vaccines. Glide's pipeline includes octreotide, teriparatide, exenatide and anthrax and influenza vaccines.
The company has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. Glide Technologies has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT. For more information please visit http://www.glide-technologies.com
Dr Mark Carnegie-Brown
Chief Executive Officer
SOURCE Glide Technologies